Musk’s Brain Chip Rival Starts Manned Tests [Video]

Founded in 2016 by Elon Musk and eight neurologists neuralinkcontinues its activities with the aim of implanting a chip in the brain. But Neuralink is not the only company operating in this field. Here is one of Musk’s biggest competitors in this regard today. from Synchron An important news has arrived.

Synchron, in the announcement it shared today, within the scope of its work called ‘COMMAND’ on the territory of the United States that the first manned tests will begin explained. In this context, the company stated that the first patient participated in the tests at Mount Sinai Hospital in New York. The new study shows that the company’s technology applicability aims to demonstrate.

The skull does not need to be opened to insert the device into the brain

Synchron aims to help severely paralyzed patients with its Stentrode device. The company provides patients with an endovascular brain implant. digital devices ability to think and control aims to gain. The device is made of a mesh-like material with 16 sensors that can expand to align the vessel wall and is connected to an electronic device that transmits brain signals from the motor cortex in the chest.

The biggest difference of Synchron from Neuralink and similar companies is that its device does not require any operation such as opening the skull. The device instead using a vein placed in the brain. Signals received in the brain are sent to the device in the chest and commands are given through the signals. Thus, it is possible to really ‘use a device by thinking’.

If the tests are successful, the device can be approved for long-term use.

If the manned tests starting in the USA are successful, the Synchron will be ready for long-term use of its device. from the US and Drug Administration (FDA) will have the opportunity to obtain the necessary approval. Within the scope of the new study, the device will be implanted in the brains of 6 patients. Once these tests are successful, studies will begin to test the effectiveness of the device. Synchron, if all goes well, will have this device in a few years. will have a chance to launch it.

The first tests were successful

The company had previously performed successful ‘SWITCH’ tests on four different patients in Australia. Within the scope of this test, patients were observed for one year. no side effects were observed. The patients were able to send messages, shop, and perform similar activities on the Internet just by thinking.

Video showing how the device is implanted in the brain and how patients use it